Repair Biotechnologies
Syracuse, NY · Biotechnology · 10 employees
Repair Biotechnologies is a preclinical biotechnology company focused on developing drugs for cholesterol and aging-related diseases. Our first-in-class Cholesterol Degrading Platform (CDP) technology is aimed at reversing atherosclerosis, familial hypercholesterolemias, and other conditions in which excess or modified cholesterol drives pathology.
Funding history
- Funding Round — $5.3M — Nov 2025
- Funding Round — $6.2M — Mar 2024
- Funding Round — $8.4M — Jun 2023
- Series pre-seed — $200K — Feb 2021
- Funding Round — $2.9M — Sep 2020
Recent signals
- Nov 25, 2025: Raised $5.3M
- Mar 26, 2024: Raised $6.2M
- Jun 16, 2023: Raised $8.4M
- Feb 23, 2021: Raised $200K in Series pre-seed
- Sep 01, 2020: Raised $2.9M
- May 07, 2019: Raised $2.2M
- Mar 25, 2019: Raised $1.3M
- Jan 23, 2019: Raised $75K
See plans & pricing → Track Repair Biotechnologies’s funding, hiring, and signals — with verified contacts — on Fundz.